Last updated: July 31, 2026
Diltiazem hydrochloride is a mature, commoditized calcium-channel blocker with broad generic availability in oral immediate-release, extended-release, and injectable forms. Its commercial profile is driven by prescription volume, hospital demand, manufacturing efficiency, and product differentiation rather than exclusivity. The original compound and major branded formulation patents have expired, while FDA-approved generic competition limits pricing power.
What is the current market position of diltiazem hydrochloride?
Diltiazem hydrochloride remains an established cardiovascular drug used for hypertension, chronic stable angina, vasospastic angina, and rate control in atrial fibrillation or atrial flutter. FDA-approved dosage forms include:
| Product type |
Principal use |
Market position |
| Immediate-release tablets |
Hypertension and angina |
Commodity generic |
| Extended-release capsules |
Once-daily hypertension and angina treatment |
Generic, with multiple release technologies |
| Extended-release tablets |
Hypertension and angina |
Generic and branded-generic competition |
| Injectable solution |
Acute rate control and certain supraventricular tachyarrhythmias |
Hospital and institutional product |
| Topical formulations |
Compounded use, including anal fissures |
Specialty and compounding channel |
The principal branded products were Cardizem, Cardizem CD, Cardizem LA, Tiazac, and Cartia XT. Most commercial prescriptions now use generic diltiazem hydrochloride supplied by multiple manufacturers, including large generic companies, specialty pharmaceutical suppliers, and contract manufacturers.
Diltiazem competes with beta blockers, verapamil, dihydropyridine calcium-channel blockers such as amlodipine, and other rate-control therapies. Its continued use reflects physician familiarity, multiple dosage forms, and low acquisition cost.
How large is the diltiazem hydrochloride market?
No single public company reports global diltiazem hydrochloride revenue as a consolidated product line. The market is fragmented among generic manufacturers, wholesalers, hospitals, pharmacies, and private-label suppliers. Commercial market reports often combine diltiazem with broader calcium-channel blocker or cardiovascular drug categories, making headline market-size figures difficult to reconcile.
The financial profile has four distinct segments:
- Retail oral generics: High volume and low unit pricing.
- Extended-release products: Higher manufacturing complexity and somewhat better pricing than immediate-release tablets.
- Injectable products: Lower prescription volume but greater institutional importance and potential supply sensitivity.
- Branded or private-label products: Limited brand premium, generally based on supply reliability, packaging, or channel relationships.
The U.S. market has experienced long-term price erosion because multiple ANDA holders compete for pharmacy and wholesaler contracts. Injectable diltiazem can have a stronger revenue profile per unit than standard tablets, but hospital purchasing remains price-sensitive and subject to formulary and group-purchasing negotiations.
What is the financial trajectory for diltiazem hydrochloride?
Diltiazem’s financial trajectory follows the standard lifecycle of an established generic cardiovascular medicine.
| Period |
Commercial phase |
Financial characteristics |
| 1980s-1990s |
Branded expansion |
Revenue supported by Cardizem and extended-release brands |
| Late 1990s-2000s |
Generic entry |
Rapid price and market-share erosion |
| 2010s |
Mature generic market |
Stable demand, low margins, multiple suppliers |
| 2020-2022 |
Supply-chain disruption |
Periodic shortages and higher manufacturing costs in some channels |
| 2023 onward |
Mature and fragmented market |
Volume remains durable; pricing depends on dosage form and supply position |
The original branded franchise generated substantial revenue before generic substitution. Sanofi’s Cardizem franchise, including oral and injectable formulations, was among the better-known commercial calcium-channel blocker portfolios in the United States. That revenue base declined after generic entry and the expiration of formulation-related exclusivity.
Current commercial value is concentrated in manufacturing scale rather than patent ownership. Companies with low-cost API access, validated extended-release production, reliable injectable capacity, and broad wholesaler contracts have the strongest competitive position.
Public-company exposure is usually indirect. Generic manufacturers generally do not disclose diltiazem revenue separately, and the product is unlikely to be material to the consolidated revenue of large diversified pharmaceutical companies. Its financial importance is greater for smaller generic firms, contract manufacturers, hospital suppliers, and companies with concentrated cardiovascular portfolios.
When did diltiazem hydrochloride lose exclusivity?
Diltiazem’s core compound exclusivity expired decades ago. The active ingredient was discovered and commercialized well before the modern Hatch-Waxman framework, and the original composition-of-matter patent could not support current commercial protection.
The principal commercial loss of exclusivity occurred through the following sequence:
| Event |
Commercial effect |
| Original diltiazem patents expired |
Generic active-ingredient competition became possible |
| Immediate-release generic approvals |
Brand tablet pricing declined |
| Extended-release generic approvals |
Cardizem CD, Tiazac, and similar products faced substitution |
| Multiple ANDA approvals |
Pharmacy and wholesaler purchasing shifted toward lowest-cost suppliers |
| Mature injectable competition |
Hospital pricing became contract-driven |
Patent-term restoration and modern regulatory exclusivity did not create a meaningful current barrier for diltiazem. Any historical formulation patents covering controlled-release bead systems, capsule structures, or release profiles have expired or no longer provide commercially relevant exclusivity.
What is the Orange Book status of diltiazem hydrochloride?
The FDA Orange Book identifies approved products, therapeutic equivalence information, and listed patents or exclusivity where applicable. Diltiazem hydrochloride has extensive generic representation across immediate-release and modified-release products.
Key Orange Book characteristics include:
- Multiple approved generic tablets and capsules.
- Therapeutic-equivalence listings for many oral products.
- Separate reference products for different release mechanisms and dosage forms.
- No current commercially meaningful composition-of-matter patent barrier.
- Product-specific regulatory requirements for extended-release formulations.
The reference products historically associated with diltiazem include Cardizem tablets, Cardizem CD, Cardizem LA, Tiazac, and related products. Generic approval does not automatically make every extended-release product substitutable for every other extended-release product. Release mechanism, strength, dosage form, labeling, and therapeutic-equivalence coding remain important.
A generic manufacturer that receives approval for an extended-release capsule may compete directly with the corresponding reference product but may not automatically substitute for an extended-release tablet with a different formulation architecture.
What patents protect diltiazem hydrochloride products?
No unexpired U.S. patent estate materially protects the diltiazem molecule itself. Commercially relevant historical patent categories included:
Composition and active-ingredient patents
The foundational diltiazem patents covered the chemical compound and related salts. Those rights expired long ago and no longer prevent generic manufacture or sale.
Extended-release formulation patents
Historical formulation patents covered:
- Sustained-release beads.
- Multiparticulate capsule systems.
- Coated drug particles.
- Controlled dissolution profiles.
- Once-daily oral delivery.
- Capsule and tablet release mechanisms.
These patents helped support branded products such as Cardizem CD and Tiazac but have reached the end of their useful patent life.
Method-of-use patents
Diltiazem labeling covers hypertension, angina, and certain supraventricular arrhythmias. Method-of-use patents associated with these indications are either expired or commercially weak because the uses are established, the product is generic, and physicians commonly prescribe the drug across overlapping cardiovascular indications.
Manufacturing patents
Manufacturing know-how may still provide practical advantages in:
- Particle-size control.
- Extended-release coating uniformity.
- Dissolution testing.
- Stability under temperature and humidity stress.
- Sterile injectable production.
- Control of impurities and degradation products.
These are operational barriers, not meaningful exclusivity rights. A competitor can design around process claims or reproduce the product using an alternative manufacturing route if it satisfies FDA requirements.
How strong is the diltiazem hydrochloride patent estate?
The patent estate is weak from an exclusivity perspective and moderate from a manufacturing and regulatory-execution perspective.
| Factor |
Assessment |
| Composition-of-matter protection |
Expired |
| Core formulation protection |
Expired |
| Method-of-use protection |
Expired or commercially limited |
| Orange Book blocking patents |
No meaningful current barrier |
| Generic substitution risk |
High |
| Manufacturing complexity |
Low for immediate-release; moderate for extended-release; high for sterile injection |
| Regulatory filing burden |
Established but product-specific |
| Pricing power |
Low |
| Supply-chain value |
Moderate, especially for injectable products |
The key remaining moat is execution. A manufacturer with dependable API sourcing and strong quality systems can compete. A manufacturer without validated dissolution, bioequivalence, or sterile-production capabilities may face approval delays, recalls, or supply interruptions.
Which companies compete in the diltiazem hydrochloride market?
Competition varies by dosage form and geography. U.S. generic suppliers have included companies such as Teva Pharmaceutical Industries, Zydus Lifesciences, Hikma Pharmaceuticals, Sandoz, Amneal Pharmaceuticals, Rising Pharmaceuticals, Apotex, and other ANDA holders. Product availability changes as companies discontinue products, transfer approvals, or enter and exit wholesaler contracts.
The competitive landscape includes:
- Large generic manufacturers: Broad portfolios, lower production costs, and national distribution.
- Specialty generic suppliers: Focus on extended-release or hospital products.
- Contract manufacturers: Produce finished dosage forms or sterile injectable products for commercial partners.
- API manufacturers: Supply diltiazem hydrochloride to finished-dose producers.
- Hospital suppliers: Sell injectable products through institutional contracts and group-purchasing organizations.
The market is less dependent on a single innovator than on the number of active suppliers. When several manufacturers remain approved and commercially active, pricing generally declines. When injectable suppliers experience manufacturing disruptions, remaining companies can gain temporary volume and pricing leverage.
What generic entry risks exist for diltiazem hydrochloride?
Generic entry risk is already realized for most diltiazem products. The relevant business question is not whether generic entry will occur, but whether additional suppliers will intensify erosion or whether supply disruptions will temporarily improve pricing.
Immediate-release tablets
Generic competition is extensive. Entry barriers are low, and price competition is severe. A new supplier would need efficient production and a distribution agreement to achieve meaningful share.
Extended-release capsules and tablets
Entry barriers are higher because the applicant must demonstrate consistent release performance and bioequivalence. The market can support better margins than immediate-release tablets, but multiple approved suppliers limit long-term pricing power.
Injectable diltiazem
The principal risks are manufacturing failure, sterile-facility constraints, recalls, and hospital-contract concentration. A supplier with an approved injectable product can benefit from temporary shortages, although hospitals may resist sustained price increases.
Are there Paragraph IV challenges involving diltiazem?
Paragraph IV litigation is no longer a central commercial issue for the mature diltiazem market. Paragraph IV certifications historically could be relevant when generic applicants challenged unexpired formulation patents for branded extended-release products. Those disputes did not preserve a current patent barrier.
For a mature product such as diltiazem, the principal ANDA risks are regulatory and commercial:
- FDA complete-response letters.
- Bioequivalence failure.
- Dissolution-profile variability.
- Manufacturing inspection findings.
- Product discontinuation.
- Failure to obtain profitable distribution.
- Price compression after additional approvals.
The absence of meaningful current patent protection shifts risk away from litigation and toward FDA execution and market access.
What FDA regulatory status applies to diltiazem hydrochloride?
Diltiazem hydrochloride is an FDA-approved prescription drug available through multiple regulatory pathways.
| Regulatory area |
Status |
| Oral immediate-release products |
Approved generic products |
| Oral extended-release products |
Approved generic and reference products |
| Injectable products |
FDA-approved institutional products |
| New chemical entity exclusivity |
Expired |
| Reference-product exclusivity |
Expired |
| Biosimilar pathway |
Not applicable |
| ANDA pathway |
Principal route for generic competition |
Diltiazem is a small-molecule drug, so biosimilar risk does not apply. Competition occurs through ANDAs and, for certain novel dosage forms or reformulations, potentially through 505(b)(2) applications.
What formulation opportunities remain for diltiazem?
The opportunity set is limited but not zero. Potential commercial differentiation includes:
- Lower-pill-burden extended-release products.
- Alternative capsule or tablet release profiles.
- Improved stability or packaging.
- Hospital-ready injectable presentations.
- Prefilled syringes or premixed infusion products, subject to regulatory requirements.
- Fixed-dose combinations.
- Specialty topical formulations.
- Products designed for adherence or supply reliability.
These opportunities require regulatory and manufacturing investment. They do not automatically create durable patent protection. A new delivery system may obtain patents, but the commercial value depends on clinical differentiation, reimbursement, switching incentives, and the ability to avoid rapid generic substitution.
What patent litigation and settlements affect diltiazem?
The major litigation cycle involved historical disputes over branded extended-release products and generic entry. Current diltiazem economics are not materially shaped by active innovator litigation or settlement agreements.
Any historical settlement terms may have affected the timing of generic launch, authorized-generic strategy, or formulation-specific entry. Those effects have largely been absorbed into the market. Current participants should focus on:
- FDA approval status.
- Active marketing status.
- Therapeutic-equivalence codes.
- Current product shortages.
- Wholesale acquisition cost and contract pricing.
- Manufacturing-site compliance.
- API supply concentration.
How does diltiazem compare with competing cardiovascular drugs?
| Drug |
Primary commercial profile |
Generic competition |
Differentiation |
| Diltiazem |
Rate control, angina, hypertension |
Extensive |
Multiple oral and injectable forms |
| Verapamil |
Rate control and hypertension |
Extensive |
Alternative non-dihydropyridine calcium-channel blocker |
| Amlodipine |
Hypertension and angina |
Extensive |
Strong once-daily hypertension position |
| Metoprolol |
Hypertension, angina, rate control, heart failure |
Extensive |
Broad cardiovascular use |
| Atenolol |
Hypertension and rate control |
Extensive |
Low-cost, older beta blocker |
| Digoxin |
Rate control and heart failure |
Generic |
Narrower therapeutic window |
Diltiazem retains a distinct position in atrial fibrillation rate control and acute hospital treatment. Its commercial advantage comes from clinical familiarity and formulation breadth rather than price or patent protection.
What is the outlook for diltiazem hydrochloride revenue?
The base-case outlook is stable volume with low pricing growth. Revenue is likely to remain concentrated in mature generic sales, while nominal market value fluctuates with:
- Generic supplier exits.
- Hospital injectable shortages.
- API and excipient costs.
- Contract renewals.
- Wholesaler inventory.
- Formulation-specific competition.
- Regulatory action affecting manufacturing sites.
Immediate-release revenue should remain structurally pressured. Extended-release and injectable products offer better opportunities for margin protection, but neither has a durable patent moat. A company seeking to build value in diltiazem would need to pair the product with a broader cardiovascular portfolio or a differentiated delivery system.
Key Takeaways
- Diltiazem hydrochloride is a mature, fully generic small-molecule drug.
- The original compound and major formulation patents have expired.
- No biosimilar pathway applies because diltiazem is not a biologic.
- Immediate-release tablets are highly commoditized and price-sensitive.
- Extended-release products retain greater manufacturing complexity but lack durable exclusivity.
- Injectable diltiazem has the strongest supply-related commercial opportunity.
- Current risks are regulatory, manufacturing, and distribution-related rather than patent-related.
- Public companies generally do not report diltiazem revenue separately.
- Revenue should remain stable in volume but constrained in price, with temporary upside during supply disruptions.
- New formulation opportunities require clinical, regulatory, and commercial differentiation to avoid generic-level economics.
FAQs
Is diltiazem hydrochloride still under patent?
No. The core diltiazem compound and commercially important historical formulation patents have expired. Current market protection comes from manufacturing capability and distribution, not patent exclusivity.
Can a company obtain FDA approval for a new diltiazem formulation?
Yes. A new formulation may proceed through an ANDA if it is sufficiently equivalent to a reference product or through a 505(b)(2) application when the product relies partly on existing FDA findings but introduces a meaningful formulation or delivery difference.
Does diltiazem have biosimilar competition?
No. Diltiazem is a synthetic small-molecule drug. Its competitors are generic versions approved primarily through the ANDA pathway.
Which diltiazem product has the strongest commercial economics?
Injectable diltiazem and technically complex extended-release products generally offer better economics than immediate-release tablets. Their advantage depends on supply reliability, manufacturing capacity, and contract access.
What would cause a diltiazem price increase?
The most likely causes are supplier exits, injectable manufacturing disruptions, FDA-related production holds, API shortages, or temporary hospital-contract imbalances. Patent expiry is no longer a driver because exclusivity has already ended.
References
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
-
U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (2024). Diltiazem hydrochloride injection prescribing information. FDA-approved labeling.
-
U.S. Food and Drug Administration. (2024). Diltiazem hydrochloride extended-release capsule prescribing information. FDA-approved labeling.
-
U.S. Food and Drug Administration. (2024). Generic drugs: Questions and answers. https://www.fda.gov/drugs/questions-answers/generic-drugs
-
DailyMed. (2024). Diltiazem hydrochloride drug labels. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/
-
U.S. Food and Drug Administration. (2024). Drug shortages. https://www.accessdata.fda.gov/scripts/drugshortages/
